Myocardial ischemia : from mechanisms to therapeutic potentials /

Saved in:

Bibliographic Details
Imprint:	New York : Springer, c2006.
Description:	1 online resource (viii, 204 p.) : ill. (some col.)
Language:	English
Series:	Basic science for the cardiologist ; 21 Basic science for the cardiologist ; 21.
Subject:	Coronary heart disease -- Pathophysiology. Coronary heart disease -- Treatment. Myocardial Ischemia -- physiopathology. Myocardial Ischemia -- therapy. Coronary heart disease -- Pathophysiology. Coronary heart disease -- Treatment.
Format:	E-Resource Book
URL for this record:	http://pi.lib.uchicago.edu/1001/cat/bib/8877436

Hidden Bibliographic Details
Other authors / contributors:	Cokkinos, Dennis V.
ISBN:	0387286578 (alk. paper) 0387286586 (e-book) 9780387286570 9780387286587 661046037X (electronic bk.) 9786610460373 (electronic bk.)
Notes:	Includes bibliographical references and index. Description based on print version record.
Other form:	Print version: Myocardial ischemia. New York : Springer, c2006 0387286578

Table of Contents:

Preface
Introduction: From Fetal to Fatal. Metabolic adaptation of the heart to environmental stress
1. The Logic of Metabolism
2. Substrate Switching and Metabolic Flexibility
3. Pleiotropic Actions of Metabolism
Chapter 1. Myocardial Ischemia. Basic concepts
1. The Pathophysiology of Ischemia and Reperfusion Injury
1.1. Cellular injury
1.2. Spread of cell injury
1.2.1. Gap junctions; cell to cell communication
1.2.2. The inflammatory response
1.3. Microvascular injury
1.4. Biochemical aspects of ischemia-reperfusion
1.5. Contractile dysfunction
1.5.1. Ischemic contracture
1.5.2. Hypercontracture
1.5.3. Myocardial Stunning
1.5.4. Myocardial Hibernation
1.6. Ischemia-reperfusion induced arrhythmias
2. Stress Signaling in Myocardial Ischemia
2.1. Membrane bound receptors
2.2. Triggers of cell signaling
2.2.1. Receptor dependent endogenous triggers
2.2.2. Non receptor triggers; reactive oxygen species and nitric oxide
2.3. Intracellular Pathways and End-Effectors
2.3.1. Protein kinase A
2.3.2. Protein kinase C
2.3.3. The Rho signaling
2.3.4. The Ras/Raf signaling
2.3.5. The PI3K signaling
2.3.6. The JAK/STAT signaling
2.3.7. Calcineurin
2.4. Transcription
2.4.1. Hypoxia inducible factor
2.4.2. Heat shock factor- Heat shock proteins
3. The Adapted Heart
3.1. Ischemic preconditioning
3.2. Heat stress induced 'cross tolerance' to myocardial ischemia
3.3. Chronic hypoxia
4. The Diseased and Ageing Heart
4.1. Cardiac hypertrophy
4.2. Heart failure
4.3. Diabetes
4.4. Hypercholesterolemia
4.5. Post-infarcted heart
4.6. Ageing heart
5. Experimental Models
6. Treatment Strategies
6.1. Pharmacological treatments
6.2. Gene and cell based therapies
Chapter 2. Hormones Signaling and Myocardial Ischemia
1. Estrogens
2. Androgens
3. Growth Hormone
4. Ghrelin
5. Glucocorticoids
6. Urocortin
7. Melanocortin Peptides
8. Melatonin
9. Erythropoietin
10. Natriuretic Peptides
11. PTH - Parathyroid Hormonerelated Peptide (PTHrP)
12. Aldosterone
13. Leptin
14. Insulin
15. Insulin Like Growth Factor (IGF-1)
16. Peroxisome Proliferated-Activated Receptors (PPARS)
17. Thyroid Hormone
17.1. Thyroid hormone receptors
Chapter 3. Ischemic Preconditioning
1. Introduction
2. Ischemic Preconditioning
3. Ischemic Preconditioning is Receptor-Mediated
4. ATP-Sensitive Potassium Channels
5. Mitochondrial K[subscript ATP] Opening Triggers Entrance Into the Preconditioned State
6. The Trigger Pathways are Divergent
7. IPC Appears to Exert Its Protection During Reperfusion by Preventing Mpt Pore Opening
8. Drugs that Protect at Reperfusion Target the Same Pathways as IPC
9. Does Reperfusion Injury Exist?
10. Clinical Implications
Chapter 4. Connexin 43 and Ischemic Preconditioning
1. Introduction
2. Regulation of Hemichannels and Gap Junctions
2.1. Protein kinase A (PKA)
2.2. cGMP-dependent protein kinases (PKG)
2.3. Protein kinase C (PKC)
2.4. Protein tyrosine kinase (PTK)
2.5. Mitogen activated protein kinases (MAPKs)
2.6. Casein kinase (CasK)
2.7. Protein phosphatases
2.8. Proton and calcium concentration
3. Myocardial Ischemia/Reperfusion Injury and Its Modification by Ischemic Preconditioning
4. Alterations in CX43 During Ischemia
5. CX43 and Ischemic Preconditioning
6. Clinical Implications
Chapter 5. Coronary Microembolization
1. Introduction
2. Coronary Blood Flow Response and Experimental Coronary Microembolization
3. Platelets, Cyclic Coronary Flow Variations and Experimental Coronary Microembolization
4. Coronary Microembolization as an Experimental Model of Unstable Angina: The Role of Inflammatory Cytokines
5. Coronary Microembolization and Ischemic Preconditioning
6. Source and Consequences of Potential Thromboemboli in Patients
7. Protection Devices Against Coronary Microembolization
8. Conclusions and Remaining Questions
Chapter 6. Fibroblast Growth Factor-2
1. Introduction
2. FGF-2 in the Heart
3. Preconditioning-Like Cardioprotection by FGF-2
4. Reperfusion (Secondary) Injury Prevention
5. Therapeutic Angiogenesis and FGF-2
6. Repair and Regeneration: Rebuilding, in Addition to Preserving, the Damaged Myocardium
7. Clinical Applications
7.1. Delivery Methods
7.2. Safety considerations
7.3. Clinical Trial Design
Chapter 7. Myocardial Protection - From Concepts to Clinical Practice
1. Background
2. Myocardial Protection
2.1. Patient status
2.1.1. Diabetes mellitus
2.1.2. Hypercholesterolemia-atherosclerosis
2.1.3. Hyperthyroidism
2.1.4. Hypothyroidism
2.2. Myocardial status
2.2.1. Myocardial hypertrophy
2.2.2. Myocardial dysfunction
3. The Stage of the Ischemia-Reperfusion Injury Cascade
4. Cardioprotective Agents
5. Synthesis
Chapter 8. A Synopsis
Index

Myocardial ischemia : from mechanisms to therapeutic potentials /

Similar Items